Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29603322 | 1.00 | CA1 (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1008899 | 0.86 | CA1 (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2478176 | 0.83 | CA1 (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4321308 | 0.81 | MAPT (0.57) | CA1CA2CA12CA7CA9 | |
| SCHEMBL19993693 | 0.81 | ALDH1A1 (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL31098108 | 0.81 | CA1 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4891137 | 0.81 | KDM4E (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11355733 | 0.81 | CA1 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL14378655 | 0.80 | CYP2A6 (0.43) | TDP1ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL9609642 | 0.80 | TSHR (0.47) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462376-A | Synthesis process of panatinib key intermediate | 湖北广济医药科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-10-14 | — | — | US | disclosed |
| CN-119462376-A | Synthesis process of panatinib key intermediate | 湖北广济医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118908899-A | FGFR4 inhibitor and preparation and application thereof | 重庆医科大学 | 2024-11-08 | — | — | CN | disclosed |
| CN-115947693-B | FGFR4 inhibitor and preparation and application thereof | 重庆医科大学 | 2024-11-05 | — | — | CN | disclosed |
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326269-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Oregon Health & Science University (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4324833-A1 | ALKYNYLPHENYLBENZAMIDE COMPOUND AND USE THEREOF | Shenzhen Newdel Biotech Co., Ltd. (CN) | 2024-02-21 | — | — | EP | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
| EP-2743266-A2 | PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON | Obshchestvo S Ogranichennoy Otvetstvennostyou "Fusion Pharma" (RU) | 2014-06-18 | — | — | EP | disclosed |
| EP-2665709-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | Sun Pharma Advanced Research Company Limited (IN) | 2013-11-27 | — | — | EP | disclosed |
| US-20130296557-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2013-11-07 | — | — | US | disclosed |
| US-20130296557-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2013-11-07 | — | — | US | disclosed |
| US-20130296557-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2013-11-07 | — | — | US | disclosed |
| CN-103214480-A | Pyrazolopyridines alkynylbenzene compound and medicinal composition and application | GUANGZHOU INST BIOMED & HEALTH | 2013-07-24 | — | — | CN | disclosed |
| WO-2012173521-A2 | PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ФЬЮЖН ФАРМА" (RU) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012098416-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098416-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | SMN1; SMN2, MCL1, NLN | CA1 4128/4885CA2 4789/4885CA12 4496/4885 |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | ALK, NTRK1, ERBB2 | CA1 4773/4885CA2 2166/4885CA12 4301/4885 |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | BRAF, RAF1, NRAS | CA1 1112/4885CA2 1425/4885CA12 2120/4885 |
| US-20130296557-A1 | DIARYLACETYLENE HYDRAZIDE CONTAINING TYROSINE KINASE INHIBITORS | ABL1, LCK, JAK2 | CA1 712/4885CA2 417/4885CA12 1090/4885 |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | CA1 3996/4885CA2 1390/4885CA12 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.